Diabetic Macular Edema
What Is Diabetic Macular Edema?
Diabetic macular edema is a complication of diabetes that develops when fluid accumulates in the macula, the small but critically important area at the center of the retina.
The macula is roughly the size of a pencil eraser, yet it contains the highest concentration of light-sensing cells in the entire retina. It provides the sharp central vision you rely on for reading, recognizing faces, and driving. When the macula swells with fluid, these tasks become noticeably more difficult.
Diabetic macular edema can occur at any stage of diabetic retinopathy and is the most common cause of vision loss in people with diabetic eye disease (National Eye Institute). While diabetic retinopathy describes changes to the blood vessels throughout the retina, DME specifically refers to swelling in the macular region. Some patients have mild retinopathy but significant macular edema, which is why separate evaluation of the macula is essential at every diabetic eye exam.
Both type 1 and type 2 diabetes can lead to DME. Your risk increases with longer diabetes duration, poorly controlled blood sugar, high blood pressure, high cholesterol, and kidney disease. Pregnancy can also accelerate diabetic eye changes, making comprehensive screening especially important for expectant mothers with diabetes.
What Causes Diabetic Macular Edema?
The underlying cause of DME is chronic damage to retinal blood vessels from prolonged high blood sugar levels.
Over time, elevated glucose weakens the walls of the tiny capillaries that nourish the retina. These weakened vessels can develop small bulges called microaneurysms, which may eventually leak plasma and other fluid components into the surrounding retinal tissue. When this leakage occurs in or near the macula, the accumulated fluid causes the retina to thicken and swell.
A protein called vascular endothelial growth factor (VEGF) plays a central role in DME. Oxygen-starved retinal tissue releases VEGF, which makes blood vessel walls more permeable and encourages the growth of fragile new vessels. This increased permeability accelerates fluid leakage into the macula, worsening edema.
Healthy retinal vessels form a tight barrier that carefully controls which substances pass into the retina. Diabetes disrupts this barrier at a cellular level, allowing proteins, lipids, and fluid to seep through. The result is not only swelling but also deposits of hard exudates, yellowish lipid collections that can further damage retinal tissue if left untreated.
Inflammation also contributes to DME. Chronic hyperglycemia triggers an inflammatory cascade within the retina, releasing cytokines and other molecules that compound vessel leakage. This is one reason why some patients who do not respond fully to anti-VEGF therapy may benefit from corticosteroid-based treatments that target the inflammatory component of the disease.
Symptoms of Diabetic Macular Edema
DME can develop gradually, and some patients may not notice changes until significant swelling has already occurred.
The most common symptom is blurry vision, particularly when trying to read or focus on fine details. Straight lines may appear wavy or bent, and colors may seem faded or washed out. These changes can affect one or both eyes and may fluctuate from day to day depending on blood sugar levels and fluid shifts.
Patients often report that reading small print becomes harder, faces appear less distinct, or driving feels less comfortable. These practical difficulties can develop so slowly that patients attribute them to aging rather than a treatable eye condition. Any new or worsening visual difficulty in a person with diabetes warrants prompt evaluation.
In many cases, DME is discovered during a routine diabetic eye screening before the patient has noticed any symptoms. This is precisely why regular dilated eye exams are so valuable for people with diabetes. Early detection allows treatment to begin before irreversible damage occurs.
How Diabetic Macular Edema Is Diagnosed
Accurate diagnosis of DME requires a thorough retinal examination combined with advanced imaging technology.
During a dilated exam, our retina specialists use special lenses to view the macula in high detail. This allows direct observation of macular thickening, microaneurysms, hard exudates, and other signs of fluid leakage. A dilated exam remains the foundation of diabetic eye assessment.
Optical coherence tomography (OCT) is the primary tool for diagnosing and monitoring DME. This noninvasive scan produces detailed cross-sectional images of the retina, allowing precise measurement of macular thickness. OCT clearly reveals fluid pockets within the retinal layers, enabling our retina specialists to track even subtle changes over time and gauge how well treatment is working.
In some cases, a fluorescein angiogram helps pinpoint the exact location and pattern of vessel leakage. A safe vegetable-based dye is injected into a vein in the arm and photographed as it travels through the retinal blood vessels. Areas of leakage light up on the images, helping guide treatment decisions, particularly when focal laser therapy is being considered.
OCT angiography (OCTA) is a newer imaging method that maps retinal blood flow without the need for dye injection. It provides detailed views of the macular capillary network and can identify areas of poor blood flow that contribute to the disease. This technology helps our team build a complete picture of how DME is affecting your retina.
Frequently Asked Questions
Anti-VEGF injections are currently the first-line treatment for most patients with DME. Medications such as aflibercept (Eylea), ranibizumab (Lucentis), bevacizumab (Avastin), and the newer faricimab (Vabysmo) are delivered directly into the eye through a tiny needle after the surface has been numbed. These medications block the VEGF protein that drives fluid leakage, allowing the macula to dry and vision to improve in many patients. Large clinical trials have shown that anti-VEGF therapy can improve vision by an average of two to three lines on an eye chart over the first year of treatment.
Focal or grid laser photocoagulation was once the standard treatment for DME and is still used in certain situations. The laser seals leaking microaneurysms and reduces fluid accumulation in the macula. While anti-VEGF injections have largely replaced laser as the primary approach, laser can be a useful supplement to reduce the frequency of injections or to treat specific patterns of leakage that respond well to targeted laser application. Our retina specialists may recommend laser therapy as part of a combined treatment plan for patients with proliferative diabetic retinopathy or persistent edema.
Blood sugar management is one of the most important factors in preventing and controlling DME. Studies consistently show that maintaining a hemoglobin A1C below 7% significantly lowers the risk of developing macular edema and slows its progression. Working with your primary care physician or endocrinologist to optimize blood sugar, blood pressure, and cholesterol gives your eye treatments the best chance of success.
In many cases, treatment can recover a meaningful amount of lost vision, especially when DME is caught early. Anti-VEGF injections have demonstrated the ability to improve visual acuity in a majority of treated patients. However, if macular edema persists for a long time or causes structural damage to the retinal cells, some vision loss may be permanent. This is why timely diagnosis and consistent follow-up are so important.
Treatment typically begins with monthly anti-VEGF injections for the first several months. As the macula responds, the interval between injections is gradually extended based on OCT imaging and vision assessments. Some patients eventually achieve long periods of stability with less frequent monitoring, while others require ongoing treatment to maintain their results. Each treatment plan is tailored to the individual response.
With current treatments, most patients with DME can maintain or improve their vision when they follow a consistent treatment and monitoring plan. The condition does require ongoing attention because the underlying diabetes continues to affect the retinal blood vessels. Regular dilated exams, adherence to your injection schedule, and diligent management of blood sugar, blood pressure, and cholesterol all contribute to the best possible long-term outcome. Conditions such as cystoid macular edema from other causes may coexist and need separate evaluation.
What our Patients say
4.8
Reviews
(3,408)